Journals / Cukurova Medical Journal / 2019 / Cilt: 44 Sayı: Ek 1

Should central sensitization and neuropathic pain be considered in disease activity and treatment decision in axial ankylosing spondilitis?

Santral sensitizasyon bozukluğu aksiyel ankilozan spondilitte hastalık aktivitesini değerlendirmede dikkate alınmalı mıdır?

Pages
1–10
Publication Date
2019-12-29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Positive correlations of central sensitization and neuropathic pain scores with disease activity scores support that chronic pain components should be taken into consideration in the follow-up of the disease

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: The aim of this study was to evaluate the prevalence of central sensitization syndromes and the relation between severity of central sensitization and disease activity in patients with axial ankylosing spondylitis (AS).
📊
Key Findings & Data:Materials and Methods: Study included 105 patients who were diagnosed with AS.
💡
Conclusion & Impact:Positive correlations of central sensitization and neuropathic pain scores with disease activity scores support that chronic pain components should be taken into consideration in the follow-up of the disease
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Ankilozan spondilit · nöropatik ağrı · hastalık aktivitesi

Abstract

Purpose: The aim of this study was to evaluate the prevalence of central sensitization syndromes and the relation between severity of central sensitization and disease activity in patients with axial ankylosing spondylitis (AS). Materials and Methods: Study included 105 patients who were diagnosed with AS. Patients' age, sex, body mass index (BMI), disease duration, accompanying disease (diabetes, hypertension) were recorded. The severity of back pain was assessed by visual analog scale (VAS), disease activity by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), and Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS_CRP). Central sensitization inventory (CSI) was used for central sensitization. Results: Central sensitization was found in 45.7% of all participants and neuropathic pain was found in 34.3% of them. When we divided the group according to the central sensitization score ≥40, we found that those who were diagnosed with central sensitization were at an advanced age and have higher BMI, higher erythrocyte sedimentation rate, longer disease duration, higher disease activity, higher neuropathic pain presence and scores than others. Conclusion: Central sensitization syndromes and neuropathic pain are frequently associated with AS. Positive correlations of central sensitization and neuropathic pain scores with disease activity scores support that chronic pain components should be taken into consideration in the follow-up of the disease

Özet

Amaç: Bu çalışmanın amacı, aksiyel ankilozan spondilit’li (AS) hastalarda santral sensitizasyon sendromlarının prevalansını ve santral sensitizasyonun şiddeti ile hastalık aktivitesi arasındaki ilişkinin değerlendirilmesidir. Gereç ve Yöntem: Çalışmamız, AS tanılı 105 hastayı içermektedir. Hastaların yaşı, cinsiyeti, vücut kitle indeksi (VKİ), hastalık süresi, eşlik eden hastalık (diyabet, hipertansiyon) kaydedildi. Bel ağrısının şiddeti görsel analog skala (VAS) ile, hastalık aktivitesi Bath Ankilozan Spondilit Hastalık Aktivite İndeksi (BASDAI), Bath Ankilozan Spondilit Fonksiyonel İndeks (BASFI) ve Ankilozan Spondilit Hastalık Aktivite Skoru-C-reaktif protein (ASDAS_CRP) ile değerlendirildi. Santral sensitizasyon için santral sensitizasyon envanteri (CSI) kullanıldı.Bulgular: Tüm katılımcıların %45.7'sinde santral sensitizasyon, (SS) % 34.3'ünde nöropatik ağrı saptandı. Grubu santral sensitizasyon skoru ≥40'a göre ayırdığımızda, santral sensitizasyon tanısı alanlarda ileri yaş, yüksek VKI, yüksek eritrosit sedimentasyon hızı (ESR), uzun hastalık süresi, yüksek hastalık aktivitesi), yüksek nöropatik ağrı varlığı ve skorları tespit ettik..Sonuç: Santral sensitizasyon sendromları ve nöropatik ağrı sıklıkla AS ile ilişkilidir. Santral sensitizasyon ve nöropatik ağrı skorlarının hastalık aktivite skorları ile pozitif korelasyonu, hastalık takibinde kronik ağrı bileşenlerinin dikkate alınması gerektiğini desteklemektedir.

🔖

Cite This Article

KOCA, T., GÖĞEBAKAN, H., ÇETİN, G. (2019). Should central sensitization and neuropathic pain be considered in disease activity and treatment decision in axial ankylosing spondilitis?. Cukurova Medical Journal, Cilt: 44 Sayı: Ek 1, 1–10. https://ajindex.com/articles/56247

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Procházková L, Červeňák V, Souček M. [Axial spondyloarthritis].Vnitr Lek. 2018 Spring;64(2):108-116.
  2. Geler-Külcü D, Batıbay S, Öztürk G, Mesci N. The association of neuropathic paIn and disease activity, functional level, and quality of life in patients with ankylosIng spondylitis: a cross-sectional study. Turk J Med Sci. 2018 Apr 30;48(2):257-265. doi: 10.3906/sag-1707-147.
  3. Salaffi F, Giacobazzi G, Di Carlo M. Chronic Pain In Inflammatory Arthritis: Mechanisms, Metrology, and Emerging Targets-A Focus on the JAK-STAT Pathway.PaIn Res Manag. 2018 Feb 7;2018:8564215. doi: 10.1155/2018/8564215. eCollection 2018.
  4. Kim MS, Koh IJ, Lee SY, In Y. Central sensitization is a risk factor for wound complications after primary total knee arthroplasty.Knee Surg Sports Traumatol Arthrosc. 2018 Mar 24. doi: 10.1007/s00167-018-4914-6. [Epub ahead of print] Ji RR, Nackley A, Huh Y, Terrando N, Maixner W. Neuroinflammation and Central Sensitization In Chronic and Widespread Pain. Anesthesiology. 2018 Feb 19. doi: 10.1097/ALN.0000000000002130. [Epub ahead of print] Nijs J, Torres-Cueco R, van Wilgen CP, Girbes EL, Struyf F, Roussel N, et al. Applying modern pain neuroscience in clinical practice: criteria for the classification of central sensitization paIn.PaIn Physician. 2014 Sep-Oct;17(5):447-57.
  5. Neblett R, Hartzell MM, Williams M, Bevers KR, Mayer TG, Gatchel RJ. Use of the Central Sensitization Inventory (CSI) as a treatment outcome measure for patients with chronic spinal pain disorder in a functional restoration program. Spine J. 2017 Dec;17(12):1819-1829. doi: 10.1016/j.spInee.2017.06.008. Epub 2017 Jun 12. Düzce E. Turkish Validity and Reliability of Central Sensitization Inventory. Thesis. Trakya University, Department of Physical Medicine and Rehabilitation. 2018
  6. Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of predominantly neuropathic origin: Validation for use In clinical and postal research. J Pain. 2005;6:149–158
  7. Bennett MI, Attal N, Backonja MM; Baron R; Bouhassira D; Freynhagen R; et al. Using screening tools to identify neuropathic pain. Pain. 2017;127(3):199-203. DOI: 10.1016/j.paIn.2006.10.034 Koc R, Erdemoglu AK. Validity and reliability of the Turkish Self-administered Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) questionnaire. Pain Med. 2010 Jul;11(7):1107-14. doi: 10.1111/j.1526-4637.2010.00837.x. Freynhagen R, Tölle TR, Gockel U, Baron R. The painDETECT project - far more than a screening tool on n